macro

Abivax rejects short seller report on its obesity drug data

Abivax says the Scorpion Capital report contains numerous inaccurate statements and points to the fund's direct financial interest in a share price decline.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

French biotech Abivax issued a statement responding to a report published on November 20, 2026 by Scorpion Capital. The company says the report contains numerous factually inaccurate and misleading claims, including ones based on studies commissioned and funded by Scorpion Capital itself.

Abivax said it is reviewing the report in detail and expects to provide further updates. It also reaffirmed its confidence in the Phase 3 ABTECT trial results and said they will support the U.S. FDA NDA filing by the end of the year.

According to Abivax, Scorpion Capital openly disclosed its short position in the company and its intention to start covering a large part of it once the report was published.

why it matters

The statement matters mainly for holders of ABVX, since a short position gives the fund a direct interest in a lower share price. The story concerns a single company and has limited relevance for the broader market.

market impact

Abivax shares: short seller report and company rebuttal add uncertainty to the stock price

tags

instruments

ABVX

sources

  1. Abivax Statement on Short Seller Report — globenewswire.com, 20 November 2026 at 21:33 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗